



Office_NNP of_IN the_DT General_NNP Counsel_NNP
B-_NNP 282318_CD
April_NNP 1_CD ,_, 1999_CD
The_DT Honorable_NNP James_NNP M_NNP ._. Jeffords_NNP Chairman_NNP The_DT Honorable_NNP Edward_NNP M_NNP ._.
Kennedy_NNP Ranking_NNP Minority_NNP Member_NNP Committee_NNP on_IN Health_NNP ,_, Education_NNP ,_,
Labor_NNP ,_, and_CC Pensions_NNP United_NNP States_NNPS Senate_NNP
The_DT Honorable_NNP Thomas_NNP J_NNP ._. Bliley_NNP ,_, Jr_NNP ._. Chairman_NNP The_DT Honorable_NNP John_NNP
D_NNP ._. Dingell_NNP Ranking_NNP Minority_NNP Member_NNP Committee_NNP on_IN Commerce_NNP House_NNP of_IN
Representatives_NNPS
Subject_NNP :_: Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP
Administration_NNP :_: Over-the-_NNP Counter_NNP Human_NNP Drugs_NNS ;_: Labeling_VBG
Requirements_NNP
Pursuant_NNP to_TO section_NN 801_CD (_( a_DT )_) (_( 2_LS )_) (_( A_DT )_) of_IN title_NN 5_CD ,_, United_NNP States_NNPS Code_NNP ,_,
this_DT is_VBZ our_PRP$ report_NN on_IN a_DT major_JJ rule_NN promulgated_VBD by_IN the_DT Department_NNP of_IN
Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP Administration_NNP (_( FDA_NNP )_) ,_,
entitled_VBN "_'' Over-the-_NNP Counter_NNP Human_NNP Drugs_NNS ;_: Labeling_VBG Requirements_NNP "_''
(_( RIN_NNP :_: 0910_CD -_: AA_NN 79_CD )_) ._. We_PRP received_VBD the_DT rule_NN on_IN March_NNP 19_CD ,_, 1999_CD ._. It_PRP was_VBD
published_VBN in_IN the_DT Federal_NNP Register_NNP as_IN a_DT final_JJ rule_NN on_IN March_NNP 17_CD ,_,
1999_CD ._. 64_CD Fed_NNP ._. Reg_NNP ._. 13254_CD ._.
The_DT final_JJ rule_NN establishes_VBZ a_DT standardized_JJ format_NN and_CC
standardized_JJ content_NN requirements_NNS for_IN the_DT labeling_VBG of_IN
over-the-counter_JJ drug_NN products_NNS ._.
The_DT final_JJ rule_NN has_VBZ an_DT announced_VBN effective_JJ date_NN of_IN April_NNP 16_CD ,_,
1999_CD ,_, which_WDT is_VBZ less_JJR than_IN the_DT 60_CD -_: day_NN delay_NN in_IN a_DT major_JJ rule_NN 's_POS
effective_JJ date_NN required_VBN by_IN the_DT Small_NNP Business_NNP Regulatory_NNP
Enforcement_NNP Fairness_NNP Act_NNP of_IN 1996_CD ._. 5_LS U_NNP ._. S_NNP ._. C_NNP §_NN 801_CD (_( a_DT )_) (_( 3_LS )_) ._. The_DT FDA_NNP
gives_VBZ no_DT reason_NN in_IN the_DT rule_NN 's_POS preamble_NN as_IN to_TO why_WRB the_DT 60_CD -_: day_NN delay_NN
provision_NN was_VBD not_RB met_VBN ._. While_IN the_DT rule_NN has_VBZ varying_VBG compliance_NN dates_NNS
that_WDT are_VBP much_JJ later_RBR than_IN the_DT announced_VBN effective_JJ date_NN of_IN the_DT rule_NN
(_( some_DT previously_RB approved_VBN products_NNS covered_VBN by_IN the_DT rule_NN have_VBP several_JJ
years_NNS to_TO become_VB compliant_NN with_IN the_DT labeling_VBG requirement_NN )_) ,_, we_PRP do_VBP
note_VB
GAO_NNP /_NN OGC-_NNP 99_CD -_: 36_CD
that_IN products_NNS which_WDT have_VBP drug_NN marketing_NN applications_NNS approved_VBN on_IN
or_CC after_IN April_NNP 16_CD ,_, 1999_CD ,_, must_MD comply_VB upon_IN approval_NN ._.
Enclosed_NNP is_VBZ our_PRP$ assessment_NN of_IN the_DT FDA_NNP 's_POS compliance_NN with_IN the_DT
procedural_JJ steps_NNS required_VBN by_IN section_NN 801_CD (_( a_DT )_) (_( 1_LS )_) (_( B_NNP )_) (_( i_NNP )_) through_IN (_( iv_NN )_)
of_IN title_NN 5_CD with_IN respect_NN to_TO the_DT rule_NN ._. Our_PRP$ review_NN indicates_VBZ that_IN the_DT
FDA_NNP ,_, with_IN the_DT exception_NN of_IN the_DT failure_NN to_TO allow_VB the_DT 60_CD -_: day_NN delay_NN ,_,
complied_VBN with_IN the_DT applicable_JJ requirements_NNS ._.
If_IN you_PRP have_VBP any_DT questions_NNS about_IN this_DT report_NN ,_, please_VB contact_NN
James_NNP W_NNP ._. Vickers_NNP ,_, Assistant_NNP General_NNP Counsel_NNP at_IN (_( 202_CD )_) 512_CD -_: 8210_CD ._. The_DT
official_NN responsible_JJ for_IN GAO_NNP evaluation_NN work_NN relating_VBG to_TO the_DT
Department_NNP of_IN Health_NNP and_CC Human_NNP Services_NNPS ,_, Food_NNP and_CC Drug_NNP
Administration_NNP ,_, is_VBZ William_NNP Scanlon_NNP ,_, Director_NNP ,_, Health_NNP Financing_NNP and_CC
Public_NNP Health_NNP Issues_NNPS ._. Mr_NNP ._. Scanlon_NNP can_MD be_VB reached_VBN at_IN (_( 202_CD )_)
512_CD -_: 7114_CD ._.
Robert_NNP P_NN ._. Murphy_NNP General_NNP Counsel_NNP
Enclosure_NNP
cc_NN :_: Ms_NNP ._. Jackie_NNP White_NNP Deputy_NNP Executive_NNP Secretariat_NNP Department_NNP of_IN
Health_NNP and_CC Human_NNP Services_NNPS
Page_NNP 2_CD GAO_NNP /_NN OGC-_NNP 99_CD -_: 36_CD
ENCLOSURE_NNP
ANALYSIS_NNP UNDER_IN 5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN 801_CD (_( a_DT )_) (_( 1_LS )_) (_( B_NNP )_) (_( i_NNP )_) -_: (_( iv_NN )_) OF_IN A_DT MAJOR_NNP RULE_NNP
ISSUED_NNP BY_NNP THE_DT DEPARTMENT_NNP OF_IN HEALTH_NN AND_CC HUMAN_NNP SERVICES_NNS ,_, FOOD_NN AND_CC
DRUG_NNP ADMINISTRATION_NNP ENTITLED_NNP "_'' OVER-THE-COUNTER_NNP HUMAN_NNP DRUGS_NNP ;_:
LABELING_NNP REQUIREMENTS_NNP "_'' (_( RIN_NNP :_: 0910_CD -_: AA_NN 79_CD )_)
(_( i_NNP )_) Cost-benefit_NNP analysis_NN
The_DT FDA_NNP performed_VBD a_DT cost-benefit_JJ analysis_NN of_IN the_DT final_JJ rule_NN ._. The_DT
analysis_NN estimates_VBZ that_IN the_DT one-time_JJ costs_NNS of_IN the_DT rule_NN to_TO be_VB about_IN
$_$ 58_CD million_CD with_IN annual_JJ recurring_VBG costs_NNS of_IN about_IN $_$ 11_CD ._. 5_LS million_CD ._.
The_DT health_NN benefits_NNS could_MD not_RB be_VB quantified_VBN by_IN the_DT FDA_NNP ,_, but_CC FDA_NNP
believes_VBZ the_DT benefits_NNS to_TO be_VB substantial_JJ ._. If_IN the_DT rule_NN prevents_VBZ 5_CD
percent_NN of_IN the_DT hospitalizations_NNS associated_VBN with_IN the_DT unintended_JJ
consequences_NNS of_IN self-medication_JJ ,_, the_DT economic_JJ savings_NNS could_MD be_VB $_$ 39_CD
million_CD annually_RB in_IN direct_JJ benefits_NNS and_CC $_$ 52_CD million_CD annually_RB from_IN
indirect_JJ benefits_NNS ._. In_IN addition_NN ,_, the_DT rule_NN is_VBZ expected_VBN to_TO produce_VB
more_RBR efficient_JJ consumer_NN search_NN activities_NNS which_WDT could_MD lead_VB to_TO time_NN
savings_NNS valued_VBN at_IN $_$ 19_CD million_CD to_TO $_$ 38_CD million_CD per_IN year_NN ._. Based_VBN on_IN the_DT
above_JJ ,_, the_DT total_JJ benefits_NNS of_IN the_DT rule_NN range_NN from_IN $_$ 110_CD ._. 5_LS million_CD to_TO
$_$ 129_CD ._. 6_CD million_CD per_IN year_NN ._.
(_( ii_NN )_) Agency_NNP actions_NNS relevant_JJ to_TO the_DT Regulatory_NNP Flexibility_NNP Act_NNP ,_,
5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 603_CD -_: 605_CD ,_, 607_CD ,_, and_CC 609_CD
The_DT preamble_NN to_TO the_DT final_JJ rule_NN contains_VBZ the_DT Final_NNP Regulatory_NNP
Flexibility_NNP Analysis_NNP conducted_VBN by_IN the_DT FDA_NNP ._.
Using_VBG the_DT Small_NNP Business_NNP Administration_NNP 's_POS size_NN designation_NN for_IN
this_DT industry_NN of_IN fewer_JJR than_IN 750_CD employees_NNS ,_, FDA_NNP estimates_VBZ that_IN 70_CD
percent_NN of_IN the_DT 400_CD firms_NNS in_IN the_DT industry_NN would_MD be_VB considered_VBN small_JJ
entities_NNS ._.
FDA_NNP finds_VBZ that_IN the_DT one-time_JJ cost_NN of_IN compliance_NN for_IN each_DT product_NN ,_,
estimated_VBN to_TO be_VB $_$ 600_CD ,_, should_MD be_VB manageable_JJ for_IN small_JJ entities_NNS even_RB
if_IN they_PRP manufacture_VBP 10_CD to_TO 20_CD products_NNS that_WDT require_VBP relabeling_VBG at_IN a_DT
cost_NN of_IN $_$ 6_CD ,_, 000_CD to_TO $_$ 12_CD ,_, 000_CD ._.
The_DT analysis_NN also_RB discusses_NNS the_DT alternatives_NNS considered_VBN such_JJ as_IN
different_JJ compliance_NN dates_NNS and_CC the_DT reasons_NNS for_IN the_DT alternative_NN
selected_VBN ._.
GAO_NNP /_NN OGC-_NNP 99_CD -_: 36_CD
(_( iii_NN )_) Agency_NNP actions_NNS relevant_JJ to_TO sections_NNS 202_CD -_: 205_CD of_IN the_DT
Unfunded_NNP Mandates_NNP Reform_NNP Act_NNP of_IN 1995_CD ,_, 2_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 1532_CD -_: 1535_CD
FDA_NNP has_VBZ found_VBN that_IN the_DT final_JJ rule_NN will_MD not_RB impose_VB a_DT mandate_NN on_IN
either_DT state_NN ,_, local_JJ ,_, or_CC tribal_NN governments_NNS or_CC the_DT private_JJ sector_NN in_IN
any_DT one_CD year_NN of_IN $_$ 100_CD million_CD or_CC more_JJR ._.
(_( iv_NN )_) Other_JJ relevant_JJ information_NN or_CC requirements_NNS under_IN acts_NNS and_CC
executive_NN orders_NNS
Administrative_NNP Procedure_NNP Act_NNP ,_, 5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 551_CD et_CC seq_NN ._.
The_DT final_JJ rule_NN was_VBD issued_VBN using_VBG the_DT notice_NN and_CC comment_VB
procedures_NNS found_VBD at_IN 5_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN 553_CD ._.
On_IN February_NNP 27_CD ,_, 1997_CD ,_, the_DT FDA_NNP published_VBD a_DT Notice_NNP of_IN Proposed_NNP
Rulemaking_NNP in_IN the_DT Federal_NNP Register_NNP ._. 62_CD Fed_NNP ._. Reg_NNP ._. 9024_CD ._. The_DT FDA_NNP
received_VBD over_IN 1_CD ,_, 800_CD comments_NNS and_CC discusses_NNS the_DT comments_NNS and_CC the_DT
changes_NNS it_PRP made_VBD to_TO the_DT proposed_VBN rule_NN in_IN the_DT preamble_NN to_TO the_DT final_JJ
rule_NN ._.
Paperwork_NNP Reduction_NNP Act_NNP ,_, 44_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 3501_CD -_: 3520_CD
The_DT final_JJ rule_NN contains_VBZ information_NN collections_NNS which_WDT are_VBP
subject_JJ to_TO review_VB by_IN the_DT Office_NNP of_IN Management_NNP and_CC Budget_NNP under_IN the_DT
Paperwork_NNP Reduction_NNP Act_NNP ._.
The_DT preamble_NN to_TO the_DT final_JJ rule_NN contains_VBZ the_DT information_NN required_VBN
by_IN the_DT Act_NNP ,_, including_VBG a_DT description_NN of_IN the_DT collection_NN ,_, the_DT reason_NN
for_IN the_DT collection_NN ,_, and_CC an_DT estimate_NN of_IN the_DT annual_JJ burden_NN hours_NNS
imposed_VBN ._.
FDA_NNP estimates_VBZ that_IN the_DT total_JJ burden_NN hours_NNS annually_RB will_MD be_VB
120_CD ,_, 578_CD with_IN 51_CD ,_, 336_CD hours_NNS being_VBG a_DT one-time_JJ burden_NN ._. The_DT burden_NN hours_NNS
are_VBP not_RB higher_JJR because_IN ,_, with_IN the_DT varied_VBN compliance_NN dates_NNS for_IN the_DT
labeling_VBG ,_, many_JJ manufacturers_NNS will_MD be_VB able_JJ to_TO change_VB the_DT labels_NNS as_IN
part_NN of_IN the_DT usual_JJ and_CC customary_JJ business_NN practice_NN of_IN redesigning_VBG
the_DT labels_NNS and_CC therefore_RB no_DT additional_JJ burden_NN is_VBZ incurred_VBN ._.
Statutory_NNP authorization_NN for_IN the_DT rule_NN
The_DT final_JJ rule_NN was_VBD issued_VBN pursuant_JJ to_TO the_DT authority_NN of_IN the_DT
Federal_NNP Food_NNP ,_, Drug_NNP ,_, and_CC Cosmetic_NNP Act_NNP and_CC the_DT Public_NNP Health_NNP Service_NNP
Act_NNP as_IN codified_VBN at_IN 21_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 321_CD ,_, 331_CD ,_, 351_CD ,_, 352_CD ,_, 353_CD ,_, 355_CD ,_, 358_CD ,_,
360_CD ,_, 360_CD b_SYM ,_, 360_CD gg-_NN 360_CD ss_NNS ,_, 371_CD ,_, 374_CD ,_, 379_CD e_SYM and_CC 42_CD U_NNP ._. S_NNP ._. C_NNP ._. §_NN §_NN 216_CD ,_, 241_CD ,_,
262_CD ,_, and_CC 264_CD ._.
Page_NNP 2_CD GAO_NNP /_NN OGC-_NNP 99_CD -_: 36_CD
Executive_NNP Order_NNP No_UH ._. 12866_CD
The_DT final_JJ rule_NN was_VBD reviewed_VBN by_IN the_DT Office_NNP of_IN Management_NNP and_CC
Budget_NNP and_CC determined_VBN to_TO be_VB an_DT economically_RB significant_JJ regulatory_JJ
action_NN and_CC approved_VBN as_IN complying_VBG with_IN the_DT order_NN ._.
Page_NNP 3_CD GAO_NNP /_NN OGC-_NNP 99_CD -_: 36_CD



